Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis

Virology

Volumn 432, Issue 1, 2012, Pages 81-90

  Fragoso Ontiveros, Verónica ^a   María Alvarez García, Rosa ^a   Contreras Paredes, Adriana ^b   Vaca Paniagua, Felipe ^a   Alonso Herrera, Luis ^b   López Camarillo, Cesar ^c   Jacobo Herrera, Nadia ^d   Lizano Soberón, Marcela ^b   Pérez Plasencia, Carlos ^a,e  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Bioinformatics; Cancer; Cervical cancer; Genomics; HPV18 variant; Molecular pathogenesis; Transcriptome

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN E6; WNT PROTEIN;

ARTICLE; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; UPREGULATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS;

DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 18; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRULENCE FACTORS;

HUMAN PAPILLOMAVIRUS;

EID: 84863993754     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.05.029     Document Type: Article

References (55)

1. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., Ferlay J. Worldwide burden of cervical cancer in 2008. Ann. Oncol. 2011, 22(12):2675-2686.
2. Bernard H.U., Chan S.Y., Manos M.M., Ong C.K., Villa L.L., Delius H., Peyton C.L., Bauer H.M., Wheeler C.M. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J. Infect. Dis. 1994, 170(5):1077-1085.
3. Berumen J., Ordoñez R.M., Lazcano E., Salmeron J., Galvan S.C., Estrada R.A., Yunes E., Garcia-Carranca A., Gonzalez-Lira G., Madrigal-de la Campa A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J. Natl. Cancer Inst. 2001, 93(17):1325-1330.
4. Bonilla-Delgado, J., Bulut, G., Liu, X., Cortés-Malagón, E.M., Schlegel, R., Flores-Maldonado, C., Contreras, R.G., Chung, S.H., Lambert, P.F., Uren, A., Gariglio, P. The E6 oncoprotein from HPV16 enhances the canonical Wnt/Β-catenin pathway in skin epidermis in'vivo. Mol Cancer Res. 10 (2), 250-258.
5. Calleja-Macías I.E., Kalantari M., Huh J., Ortiz-Lopez R., Rojas-Martinez A., Gonzalez-Guerrero J.F., Williamson A.L., Hagmar B., Wiley D.J., Villarreal L., Bernard H.U., Barrera-Saldaña H.A. Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 2004, 319(2):315-323.
6. Calleja-Macías I.E., Villa L.L., Prado J.C., Kalantari M., Allan B., Williamson A.L., Chung L.P., Collins R.J., Zuna R.E., Dunn S.T., Chu T.Y., Cubie H.A., Cuschieri K., von Knebel-Doeberitz M., Martins C.R., Sanchez G.I., Bosch F.X., Munoz N., Bernard H.U. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J. Virol. 2005, 79(21):13630-13640.
7. Contreras-Paredes A., De la Cruz-Hernández E., Martínez-Ramírez I., Dueñas-González A., Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 2009, 383(1):78-85.
8. De Boer M.A., Peters L.A., Aziz M.F., Siregar B., Cornain S., Vrede M.A., Jordanova E.S., Fleuren G.J. Human papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries. Int. J. Cancer 2005, 114(3):422-425.
9. Draghici S., Khatri P., Tarca A.L., Amin K., Done A., Voichita C., Georgescu C., Romero R. A systems biology approach for pathway level analysis. Genome Res. 2007, 17(10):1537-1545.
10. Duffy C.L., Phillips S.L., Klingelhutz A.J. Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. Virology 2003, 314(1):196-205.
11. Dumbauld D.W., Michael K.E., Hanks S.K., García A.J. Focal adhesion kinase-dependent regulation of adhesive forces involves vinculin recruitment to focal adhesions. Biol. Cell 2010, 102(4):203-213.
12. Fletcher, S.J., Poulter, N.S., Haining, E.J., Rappoport, J.Z., 2012. Clathrin-mediated endocytosis regulates occludin, and not focal adhesion, distribution during epithelial wound healing. Biol. Cell. 104 (4), 238-256.
13. Garner-Hamrick P.A., Fostel J.M., Chien W.M., Banerjee N.S., Chow L.T., Broker T.R., Fisher C. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J. Virol. 2004, 78(17):9041-9050.
14. Gen Y., Yasui K., Zen K., Nakajima T., Tsuji K., Endo M., Mitsuyoshi H., Minami M., Itoh Y., Tanaka S., Taniwaki M., Arii S., Okanoue T., Yoshikawa T. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. Cancer Lett. 2009, 275(1):27-34.
15. Giannoudis A., Herrington C.S. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 2001, 193(3):295-302.
16. Giavazzi R., Foppolo M., Dossi R., Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J. Clin. Invest. 1993, 92(6):3038-3044.
17. Gille J., Reisinger K., Asbe-Vollkopf A., Hardt-Weinelt K., Kaufmann R. Ultraviolet-A-induced transactivation of the vascular endothelial growth factor gene in HaCaT keratinocytes is conveyed by activator protein-2 transcription factor. J. Invest. Dermatol. 2000, 115(1):30-36.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
19. Ji J., Zheng P.S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol. Oncol. 2010, 117(1):103-108.
20. Karen J., Wang Y., Javaherian A., Vaccariello M., Fusenig N.E., Garlick J.A. 12-O-tetradecanoylphorbol-13-acetate induces clonal expansion of potentially malignant keratinocytes in a tissue model of early neoplastic progression. Cancer Res. 1999, 59(2):474-481.
21. Kerr M.K., Churchill G.A. Experimental design for gene expression microarrays. Biostatistics 2001, 2:183-201.
22. Khatri P., Sellamuthu S., Malhotra P., Amin K., Done A., Draghici S. Recent additions and improvements to the Onto-Tools. Nucleic Acids Res. 2005, 33:W762-W765.
23. Kim M.K., Kim T.J., Sung C.O., Choi C.H., Lee J.W., Kim B.G., Bae D.S. High expression of mTOR is associated with radiation resistance in cervical cancer. J. Gynecol. Oncol. 2010, 21(3):181-185.
24. Lai C.H., Hsueh S., Hong J.H., Chang T.C., Tseng C.J., Chou H.H., Huang K.G., Lin J.D. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. Int. J. Gynecol. Cancer 1999, 9(1):28-36.
25. Liang C.C., Park A.Y., Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2007, 2(2):329-333.
26. Lichtig H., Gilboa D.A., Jackman A., Gonen P., Levav-Cohen Y., Haupt Y., Sherman L. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology 2010, 396(1):47-58.
27. Lizano M., Berumen J., Guido M.C., Casas L., García-Carrancá A. Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J. Natl. Cancer Inst. 1997, 89(16):1227-1231.
28. Lizano M., De la Cruz-Hernández E., Carrillo-García A., García-Carrancá A., Ponce de Leon-Rosales S., Dueñas-González A., Hernández-Hernández D.M., Mohar A. Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol. Oncol. 2006, 102(2):230-235.
29. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int. J. Cancer 1996, 69(5):364-368.
30. López-Saavedra A., González-Maya L., Ponce-de-León S., García-Carrancá A., Mohar A., Lizano M. Functional implication of sequence variation in the long control region and E2 gene among human papillomavirus type 18 variants. Arch. Virol. 2009, 154(5):747-754.
31. Miles F.L., Pruitt F.L., van Golen K.L., Cooper C.R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metastasis 2008, 25(4):305-324.
32. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
33. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348(6):518-527. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.
34. Murray D., Horgan G., Macmathuna P., Doran P. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br. J. Cancer 2008, 99(8):1322-1329.
35. Ong C.K., Chan S.Y., Campo M.S., Fujinaga K., Mavromara-Nazos P., Labropoulou V., Pfister H., Tay S.K., ter Meulen J., Villa L.L. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J. Virol. 1993, 67(11):6424-6431.
36. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2005, 55(2):74-108.
37. Pérez-Plasencia C., Vázquez-Ortiz G., López-Romero R., Piña-Sanchez P., Moreno J., Salcedo M. Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways. Infect. Agents Cancer 2007, 2:16.
38. Pérez-Plasencia C., Dueñas-Gonzalez A., Alatorre-Tavera B. Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. Int. Arch. Med. 2008, 1(1):10.
39. Pieler R., Sanchez-Cabo F., Hackl H., Thallinger G.G., Trajanoski Z. ArrayNorm: comprehensive normalization and analysis of microarray data. Bioinformatics 2004, 20(12):1971-1973.
40. Qi J., Chen N., Wang J., Siu C.H. Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway. Mol. Biol. Cell 2005, 16(9):4386-4397.
41. Rodríguez L.G., Wu X., Guan J.L. Wound-healing assay. Methods Mol. Biol. 2005, 294. 23-29.
42. Rose B.R., Thompson C.H., Zhang J., Stoeter M., Stephen A., Pfister H., Tattersall M.H., Cossart Y.E. Sequence variation in the upstream regulatory region of HPV 18 isolates from cervical cancers. Gynecol. Oncol. 1997, 66(2):282-289.
43. Stewart A.C., Eriksson A.M., Manos M.M., Muñoz N., Bosch F.X., Peto J., Wheeler C.M. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J. Virol. 1996, 70(5):3127-3136.
44. Tidy J.A., Vousden K.H., Farrell P.J. Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet 1989, 1(8649):1225-1227.
45. Tornesello M.L., Duraturo M.L., Salatiello I., Buonaguro L., Losito S., Botti G., Stellato G., Greggi S., Piccoli R., Pilotti S., Stefanon B., De Palo G., Franceschi S., Buonaguro F.M. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J. Med. Virol. 2004, 74(1):117-126.
46. Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen M., Kampf C., Wester K., Hober S., Wernerus H., Björling L., Ponten F. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 2010, 28(12):1248-1250.
47. Uhlén M., Björling E., Agaton C., Szigyarto C.A., Amini B., Andersen E., Andersson A.C., Angelidou P., Asplund A., Asplund C., Berglund L., Bergström K., Brumer H., Cerjan D., Ekström M., Elobeid A., Eriksson C., Fagerberg L., Falk R., Fall J., Forsberg M., Björklund M.G., Gumbel K., Halimi A., Hallin I., Hamsten C., Hansson M., Hedhammar M., Hercules G., Kampf C., Larsson K., Lindskog M., Lodewyckx W., Lund J., Lundeberg J., Magnusson K., Malm E., Nilsson P., Odling J., Oksvold P., Olsson I., Oster E., Ottosson J., Paavilainen L., Persson A., Rimini R., Rockberg J., Runeson M., Sivertsson A., Sköllermo A., Steen J., Stenvall M., Sterky F., Strömberg S., Sundberg M., Tegel H., Tourle S., Wahlund E., Waldén A., Wan J., Wernérus H., Westberg J., Wester K., Wrethagen U., Xu L.L., Hober S., Pontén F. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 2005, 4(12):1920-1932.
48. Uren A., Fallen S., Yuan H., Usubütün A., Küçükali T., Schlegel R., Toretsky J.A. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 2005, 65(14):6199-6206.
49. van Amerongen R., Berns A. Re-evaluating the role of Frat in Wnt-signal transduction. Cell Cycle 2005, 4(8):1065-1072.
50. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1(3):1112-1116.
51. Villa L.L., Sichero L., Rahal P., Caballero O., Ferenczy A., Rohan T., Franco E.L. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J. Gen. Virol. 2000, 81(Pt 12):2959-2968.
52. Voura E.B., Ramjeesingh R.A., Montgomery A.M., Siu C.H. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Biol. Cell 2001, 12(9):2699-2710.
53. Wang S., Yu W.M., Zhang W., McCrae K.R., Neel B.G., Qu C.K. Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis. J. Biol. Chem. 2009, 284(2):913-920.
54. Xi L.F., Koutsky L.A., Galloway D.A., Kuypers J., Hughes J.P., Wheeler C.M., Holmes K.K., Kiviat N.B. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 1997, 89(11):796-802.
55. Xi L.F., Koutsky L.A., Hildesheim A., Galloway D.A., Wheeler C.M., Winer R.L., Ho J., Kiviat N.B. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol. Biomarkers Prev. 2007, 16(1):4-10.